| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.2 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.3 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.051 | 0.3 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.057 | 0.3 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |